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Background: Neurofibromatosis 1 (NF1) is the most common autosomal dominant disorder, with an incidence of
1 in 2,500-3,300 live births. NF1 is associated with significant morbidity and mortality because of complications,
especially malignant peripheral nerve sheath tumors (MPNSTs), which mainly develop during adulthood. We
evaluated our experience with management of NF1 with MPNSTs by standard chemotherapy with anthracycline
and/or ifosfamide in terms of time to treatment failure and overall survival.
Methods: We performed a retrospective review of consecutive patients with NF1 and a diagnosis of MPNSTs
between 1993 and 2003 in our referral center for NF1. Prognostic factors were evaluated by univariate analysis.
Results: We evaluated data for 21 patients with grade 1 (n=1), grade 2 (n=8) and grade 3 (n=12) MPNST; 16
presented localized disease and underwent surgery: margins for 6 were tumor-free (including 3 patients with
amputation), 2 showed microscopic residual disease and 8 showed macroscopic residual disease. All patients
received chemotherapy and 9 radiotherapy. Median time to treatment failure and overall survival were 7.8 and
17 months, respectively. Two patients were still alive at 138 and 167 months. We found no significant relationship
between type of chemotherapy and time to treatment failure or overall survival.
Conclusions: MPNSTs are highly aggressive in NF1. Conventional chemotherapy does not seem to reduce
mortality, and its role must be questioned. Recent advances in the molecular biology of MPNSTs may provide new
prognostic factors and targeted therapies.
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Malignant peripheral nerve sheath tumors (MPNSTs)
are uncommon, representing about 5% of soft-tissue sar-
comas. Neurofibromatosis 1 (NF1) is one of the most
common autosomal dominant disorders, with an inci-
dence of 1 in 2,500-3,300 live births. It is associated with
mutation in Nf1, a tumor suppressor located on chro-
mosome 17q11.2. Nf1 encodes neurofibromin, a protein
of the ras signal transduction pathway [1]. NF1 is* Correspondence: laurence.allanore@hmn.aphp.fr
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reproduction in any medium, provided the orcharacterized by neurofibromas, café au lait spots, inter-
triginous freckling, bone malformations, learning disabil-
ities and iris hamartomas [1].
NF1 has a significant morbidity and mortality because
of various complications, especially benign and/or malig-
nant tumors. Neurofibromas are benign tumors mostly
composed of Schwann cells, perineurium like-cells, fi-
broblasts and mast cells. Cutaneous neurofibromas
greatly affect quality of life; subcutaneous, nodular and
internal neurofibromas act mainly through compression
and can transform into MPNSTs. Several clinical fea-
tures such as internal or subcutaneous neurofibromas
are predictors of mortality with NF1 [1,2]. Patients with
subcutaneous neurofibromas are 3 times more likely to
have internal plexiform neurofibromas and MPNSTs. InLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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are 20 times more likely to develop [1]. The overall risk
of cancer is more than three-fold greater than in the
general population, and MPNSTs are the leading cause
of death during adulthood [3,4]. Hence, the lifetime risk
of MPNSTs is about 8% to 13% [5-8].
An enlarged mass, neurological deficits and pain can
predict malignant transformation of MPNSTs [9]. These
NF1 MPNSTs are associated with poor prognosis; the 5-
year survival rate is between 16% and 38% [7,10-15].
Limited disease is treated by wide excision along with
radiation therapy for high-risk tumors defined as
intermediate- to high-grade deep tumors with a diam-
eter >5 cm [16]. Adjuvant chemotherapy is not standard
treatment in adult-type soft-tissue sarcomas and can be
proposed for high-risk tumors. Extensive disease is
treated with anthracycline-based chemotherapy. Ifos-
famide may be discussed for patients with good per-
formance status [16].
Here we retrospectively examined our experience with
the management of MPNSTs by standard chemotherapy
with anthracycline and/or ifosfamide in patients with
NF1 and evaluated prognostic factors of time to treat-
ment failure and overall survival.
Methods
Patients
We included data for all consecutive NF1 patients with a
diagnosis of MPNST between February 1993 and
November 2003 who underwent chemotherapy in our
institution, a French national referral center for neurofi-
bromatoses. Data on clinico-pathological features and
other variables were collected from medical charts and
included medical history; demographic characteristics
(gender, age); clinical presentation, including pain, motor
or sensitive deficits, tumor location and size (the largest
diameter assessed by CT or MRI before surgery and/or
chemotherapy); intraoperative and macroscopic patho-
logical evaluation; metastatic status; histopathological
grade of the primary tumor according to the Federation
Nationale des Centres de Lutte Contre le Cancer
(FNCLCC) classification [17]; clinical evolution; and
treatment-related variables (type of surgery, chemotherapy
and radiotherapy). Initial staging was based on chest and
abdomen CT scans.
A multidisciplinary medical team validated all treat-
ments according to local and national guidelines. Sur-
gery was performed to achieve local control with tumor-
free margins. Extent of tumor resection was evaluated
from the surgeon’s notes, charts and pathological re-
ports. Surgical resection was considered macroscopically
complete (no visible tumor remaining) or incomplete
(R2=gross tumor remaining post-operatively). Micro-
scopically, tumor margins were defined as involved(R1=residual disease) or tumor-free (R0). Postoperative
radiotherapy involved irradiation of all dissected tissues
with a large field. Radiation therapy was administered at
a dose of 50–66 Gy, from 1.8 to 2 Gy. Chemotherapy in-
volved 6 cycles of doxorubicin, 60 mg/m2, delivered
every 21 days. Ifosfamide, 2500 mg/m2, was given at days
1–3 for patients with performance status 0–1. Patients
received doxorubicin and/or ifosfamide or another regi-
men, depending on their performans status and past
medical history.
All patients were followed until death or the last
known visit. Patients who underwent surgery were seen
1 month after hospital discharge. Every 3 months there-
after, physical and radiological examinations were
performed. Recurrence was defined as tumor growth oc-
curring at the excision site at least 3 months after the
initial surgery (local recurrence) and/or new distant le-
sions (metastatic recurrence). Follow-up data included
time to recurrence and type of recurrence (local and/or
metastatic). Patients with advanced disease underwent
physical examination before each chemotherapy cycle
and CT scan every 3 cycles. Time to treatment failure
was defined as time between diagnosis and recurrence.
Statistical analysis
Descriptive variables (clinical, demographic, and bio-
logical) are represented with median (range) for conti-
nuous data and categorical variables with frequency
(percentages) with 95% confidence intervals (95% CIs).
Chemotherapy regimen (single versus double agent) was
used to stratify time to treatment failure and overall sur-
vival analyses. Survival curves were plotted by the Kaplan-
Meier method. We could not perform multivariate ana-
lysis because of the small sample size. Thus, we performed
univariate regression analysis by the Cox proportional haz-
ards model to explore the effect of explanatory variables
such as anatomic location, age, tumor size, histological
grade, gender and chemotherapy regimen on time to treat-
ment failure and overall survival, estimating hazard ratios
(HRs) and 95% CIs.
All statistical tests were two-sided with p < 0.05 con-
sidered statistically significant. Statistical analysis in-
volved use of SPSS v15.1 (SPSS Inc., Cary, NC, USA)
and EpiInfo v3.4.2 (Centers for Disease Control and Pre-
vention, Atlanta, GA, USA).
Results
We included data for 21 patients (9 females; median age
31 years [range 18–79 years]). Patient characteristics are
in Table 1. Primary tumors were located on extremities
(n=8), abdomen or pelvis (n=6), trunk (n=4), and head
or neck (n=3). The median tumor diameter was 13 cm
[3–28 cm]. Pain, growing mass or neurological disorders
was found in 20, 19 and 10 patients, respectively.
Table 1 Patient and tumor characteristics for 21 patients
with neurofibromatosis 1 and a diagnosis of malignant
peripheral nerve-sheath tumors between 1993 and 2003
Age, years
Median (range) 31 (18–79)
Tumor size, cm




Metastases at diagnosis, n (%)
Absent 18 (86)
Present 3 (14)
Type of surgery, n (%)
R0, complete resection 1 (5)
R1, incomplete resection (microscopically) 3 (14)
R2, incomplete resection (macroscopically) 7 (33)
No surgery 10 (48)




Pathological staging, n (%)
T1 3 (14)
T2 18 (86)
Tumor site, n (%)
Head and neck 3 (14)
Trunk 4 (19)
Extremity 8 (38)
Abdomen or pelvis 6 (29)
Chemotherapy, n (%)
Single agent 6 (29)
Combination 15 (71)
Type of chemotherapy, n (%)
Doxorubicin 5 (24)
Ifosfamide 1 (5)
Ifosfamide + anthracycline 11 (52)
Ifosfamide + anthracycline + platinum salt 4 (19)
Abbreviations: FNCLCC Federation Nationale des Centres de Lutte Contre le
Cancer; T tumor.
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(n=1, 4.8%), 2 (n=8, 38.1%) and 3 (n=12, 57.1%). At the
time of initial diagnosis, 16 patients presented localized
disease and were candidates for curative resection. How-
ever, only 8 underwent complete macroscopic resection.
For these patients, tumor margins were classified as R1
(n=2) and R0 (n=6). The flow for surgery is presented inFigure 1. Three patients underwent amputation to achieve
tumor-free margins.
For patients with R0 margins after resection, adjuvant
treatment included chemotherapy (n = 3), radiotherapy
(n = 2), or both (n = 1). Four of the 6 patients with R0
margins experienced metastatic recurrence at 3, 6, 8 and
12 months, respectively. Among the 4 patients who had
received chemotherapy, 2 showed metastatic recurrence
at 3 and 12 months, 1 patient showed local recurrence
at 31 months (in a patient who had not received
radiotherapy), and 1 showed contralateral MPNST at 33
months, followed by a third MPNST during follow-up
(Figure 2a). This latter patient had undergone amputa-
tion for a 26-cm grade 3 tumor. The 2 other patients
who underwent amputation died of metastatic disease.
The 2 patients with R1 margins after surgery received
chemotherapy (n=2), with radiotherapy (n=1), but both
experienced metastatic progression, at 3 and 18 months,
respectively (Figure 2b).
Macroscopically incomplete resection (R2) was due to
an internal location with large tumor size. The 8 patients
with R2 status after surgery received post-operative pal-
liative chemotherapy. Five also received radiotherapy
that delivered a total dose of 50 Gy (n=4) or 30 Gy
(n=1) before (n=3) or after the end (n=2) of the first-line
chemotherapy. Four of the 8 patients showed rapid dis-
ease progression with chemotherapy.
Five patients did not undergo surgery and received only
palliative chemotherapy. They showed progressive disease
after 2, 5, 5, 7 and 9 months, respectively (Figure 2c).
All 21 patients showed treatment failure, with median
time to treatment failure 7.8 months (range 2.1–128
months). At the time of the last follow-up (December
2012), 19 patients were dead, all due to cancer; 2 were
still alive at 138 and 167 months, respectively, of follow-
up. The first patient experienced 2 other MPNSTs and
the second local recurrence, which was treated with sur-
gery and radiotherapy. Both had localized grade 3 tu-
mors with R0 resection (1 had an amputation) followed
by chemotherapy early after surgery (6 and 32 days, re-
spectively, as compared to a median of 101 days for the
series). The chemotherapy regimen was ifosfamide and
doxorubicin and was not associated with radiotherapy.
Survival at 12, 18 and 24 months was 81% (95% CI 76.4–
86.6%), 47.6% (43–52.2%) and 38% (33.4–42.6%), respect-
ively. The median overall survival for the entire cohort was
17 months (range 2.5–167 months) (Figures 3 and 4). The
median time to survival for patients with peripheral
MPNSTs was 21.4 months (range 14–137 months) and for
patients with axial MPNSTs, 12.6 months (range 2.5–167
months, p=0.4). Univariate analysis revealed no association
of variables examined and time to treatment failure or
overall survival. Increased tumor size at diagnosis was as-
sociated with a short time to treatment failure (HR=2.7,
Patients with malignant 












Figure 1 Flow-chart for surgery.
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8.9). As compared with locally advanced or metastatic dis-
ease, R0 and R1 status was associated with reduced risk of
death [HR 0.24, 0.05–1.17; p=0.08]. Because of the small
number of patients, we could not identify factors associ-
ated with the 2 amputation failures.
Discussion
In our experience managing NF1 with MPNSTs by
chemotherapy, overall survival was poor, with a median
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Figure 2 Outcome of patients after initial treatment: a) R0 patients, b
tumor remaining post-operatively, R1=microscopic involved margins (residuAlthough a difference in survival between sporadic
and NF1-related MPNSTs is still a matter of debate, sev-
eral studies showed that the prognosis of patients with
NF1 is poor [7,10,12,14,18]. This poor outcome can be
explained by several points. For most of our patients,
MPNSTs had a deep location, with large dimensions and
high histological grade (poorly or undifferentiated tu-
mors in 12 patients), as previously shown [11,12]. We
reveal a low rate of complete surgery according to the
localization and size of lesions at diagnosis: only 6 of the
21 patients had R0 resection, and local control rate wasadjuvant CT alone,
n= 3
 mo second MPSNT 33 mo local recurrence 31mo metastatic recurrence 3 mo
adj CT+RT, n= 1
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Figure 3 Kaplan-Meier curve for disease-free survival for 21 patients with malignant peripheral nerve-sheath tumors.
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previously shown [15]. In contrast, for patients with per-
ipheral MPNSTs, survival was better, although not signifi-
cantly, than with axial MPNSTs (median overall survival
of 21.4 and 12.6 months, respectively; p=0.4). This finding
can be explained by internal MPNSTs (in the abdomen,
pelvis, chest, etc.) usually remaining asymptomatic until
they reach a large size, whereas 5-year survival is better
with MPNSTs < 5 cm [8,12]. Enlarged mass, neurological
deficit and pain are clinical factors associated with malig-
nant transformation [9]. These factors are more likely to
be noted in peripheral than internal lesions.
Our series emphasizes the important role of surgery in
the management of MPNST. Indeed, the 2 surviving pa-
tients underwent surgery with R0 margins, requiring
amputation in 1. We were not able to identify any prog-
nostic factor associated with survival in these patients,
but we noted that both had received doxorubicin and

















Figure 4 Kaplan-Meier curve for overall survival for 21 patients with mRegarding amputation, our data are consistent with lit-
erature: for the 3 patients who underwent amputation,
only one survived. Non-conservative surgery is associ-
ated with better local control but not with better survival
in these patients, as previously reported [13]. We lack a
reliable prognostic factor of success for these non-
conservative surgical strategies. Further studies should
be performed to identify prognostic factors, and to
evaluate the role of neo-adjuvant treatments. A study of
neo-adjuvant isolated limb perfusion with tumor necro-
sis factor showed partial response in 3/4 patients with
MPNST [19].
All our patients receiving chemotherapy experienced
treatment failure. The place of chemotherapy in the
management of NF1 with MPNSTs is still controversial
[20]. In the adjuvant setting, chemotherapy is considered
optional but is largely used (up to 40% of NF1 patients
[18]), although doxorubin regimens have failed to show
a benefit for local recurrence, distant recurrence, overall100 150 200
95% CI
alignant peripheral nerve-sheath tumors.
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with ifosfamide might improve prognosis but with more
toxicity.
Metastatic MPNSTs have poor prognosis, and all our
patients receiving chemotherapy without surgery for ad-
vanced or metastatic diseases experienced disease progres-
sion. Chemotherapy is considered palliative in metastatic
diseases [20]. Indeed, partial response rates are about 25%
to 30% [8,22].
In our retrospective experience, alternative strategies, in-
cluding targeted therapy, were considered. Significant ad-
vances in the pathophysiologic features of NF1 have led to
considering this new therapeutic approach. MPNSTs
present complex chromosomic alterations and additional
genetic mutations (p53 and cyclin-dependent kinase in-
hibitor 2A) that are involved in malignant transformation
[23]. Loss of Nf1 gene expression induces lack of neuro-
fibromin synthesis, a GTPase activating molecule that nor-
mally inactivates Ras and inhibits cell proliferation [24].
Aberrant activation of the Ras pathway in NF1 leads to
cell proliferation. Furthermore, several signaling pathways
involved in angiogenesis (cyclooxygenase 2, vascular endo-
thelial growth factor A), cellular regulation (MKI67 etc.),
epidermal growth factor (EGF receptor, pAKT, etc.) and
Sonic hedgehog–Gli pathways are modified in plexiform
neurofibromas associated with transformation [25].
Targeted therapies have had interesting results with
NF1 tumors. Mammalian target of rapamycin inhibitors
are considered a potential therapeutic approach [26-28].
More recently, preclinical studies have provided a ra-
tionale for testing mitogen-activated protein/endothelial
regulated kinase inhibitors in NF1 clinical trials [29].
Conclusions
MPNSTS are currently treated as other soft-tissue sarco-
mas, because they are too rare to perform trials with
a sufficient number of patients. Overall survival with
MPNSTS is poor, and the usual chemotherapy used for
soft-tissue sarcomas does not improve the outcome. Re-
cent advances in the molecular biology of MPNSTS may
provide new targeted therapies.
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